The estimated Net Worth of Christopher A Marlett is at least $1.89 Million dollars as of 23 December 2019. Christopher Marlett owns over 36,647 units of Cue Biopharma Inc stock worth over $462,680 and over the last 12 years Christopher sold CUE stock worth over $1,426,672.
Christopher has made over 12 trades of the Cue Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Christopher sold 24,700 units of CUE stock worth $402,116 on 27 December 2019.
The largest trade Christopher's ever made was selling 36,647 units of Cue Biopharma Inc stock on 23 December 2019 worth over $630,328. On average, Christopher trades about 9,720 units every 20 days since 2012. As of 23 December 2019 Christopher still owns at least 784,203 units of Cue Biopharma Inc stock.
You can see the complete history of Christopher Marlett stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is 21 Erie St, Cambridge, MA 02139, USA.
Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher, and Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Cue Biopharma Inc executives and other stock owners filed with the SEC include: